Información del artículo
Las quinolonas actúan inhibiendo enzimas (topoisomerasas) indispensables en la síntesis del ADN. Tienen una actividad bactericida que depende de la concentración. Su espectro se ha ido ampliando, sobre todo desde la introducción de un átomo de flúor en la posición 6 (fluoroquinolonas)
Se usan en una gran variedad de infecciones como tratamiento de elección o alternativo, tanto a nivel hospitalario como extrahospitalario. Según el compuesto se emplean en infecciones del tracto urinario, enfermedades de transmisión sexual, osteomielitis crónica, infecciones del tracto respiratorio e infecciones sistémicas graves, entre otras
El surgimiento y extensión de resistencia a quinolonas ha limitado su uso en algunos casos y puede condicionarlo en el futuro en otros. Existen estrategias para minimizar la extensión de la resistencia. Son bien toleradas y seguras. Los efectos adversos más frecuentes se observan a nivel gastrointestinal y del sistema nervioso central
Palabras clave:
Quinolonas
Fluoroquinolonas
Agentes antimicrobianos
Revisión
Quinolones
Quinolones act by inhibiting enzymes (topoisomerases), which are indispensable to DNA synthesis. Their bactericidal activity is concentration-dependent. Their spectrum has become broader, especially since the introduction of a fluorine atom at position 6 (fluoroquinolones)
They are used as the treatment of choice or as alternative therapy in a wide variety of infections, both in the hospital and non-hospital setting. Depending on the compound, they are used in urinary tract infections, sexually transmitted diseases, chronic osteomyelitis, respiratory tract infections, and severe systemic infections, among others
The upsurge and extent of quinolone resistance has limited the use of these agents in some cases and in future may determine their use in others. There are strategies to minimize the spread of resistance. Quinolones are safe and well tolerated. The most frequent adverse effects are gastrointestinal and those affecting the central nervous system
Key words:
Quinolones
Fluoroquinolones
Antimicrobial agents
Review
El Texto completo está disponible en PDF
Bibliografía
[1.]
L.R. Peterson.
Quinolone molecular structure-activity relationships: What we have learned about improving antimicrobial activity.
Clin Infect Dis, 33 (2001), pp. 180-186
[2.]
J.M. Domagala.
Structure-activity and structure-side effect relationships for the quinolone antibacterials.
J Antimicrob Chemother, 33 (1994), pp. 685-706
[3.]
K.B. Naber, D. Adam.
Classification of fluorquinolones.
Int J Antimicrob Agents, 10 (1998), pp. 255-257
[4.]
J.r. Owens RC, P.G. Ambrose.
Clinical use of the fluoroquinolones.
Med Clin North Am, 84 (2000), pp. 1447-1469
[5.]
E. Bergogne-Berezin.
Clinical role of protein binding of quinolones.
Clin Pharmacokinet, 41 (2002), pp. 741-750
[6.]
R.C. Walker.
The fluoroquinolones.
Mayo Clin Proc, 74 (1999), pp. 1030-1037
[7.]
G.W. Amsden, C.H. Ballow, J.S. Jr. Bertino.
Pharmacokinetics and pharmacodynamics of anti-infective agents.
Principles and practice of infectious diseases. 5th ed, pp. 253-261
[8.]
P.D. Lister, C.C. Sanders.
Pharmakodinamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae.
J Antimicrob Chemother, 43 (1999), pp. 79-86
[9.]
J.I. Alós, J. Oteo, B. Aracil, J.L. Gómez-Garcés.
Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain.
J Antimicrob Chemother, 48 (2001), pp. 145-148
[10.]
D.C. Hooper.
Mechanism of action of antimicrobials: Focus on fluoroquinolones.
Clin Infect Dis, 32 (2001), pp. 9-15
[11.]
F.J. Schmitz, P.G. Higgins, S. Mayer, A.C. Fluit, A. Dalhoff.
Activity of quinolones against Gram-positive cocci: Mechanism of drug action and bacterial resistance.
Eur J Clin Microbiol Infect Dis, 21 (2002), pp. 647-659
[12.]
K. Drlica, X.L. Zhao.
DNA gyrase, topoisomerase IV, and the 4-quinolones.
Microbiol Mol Biol Rev, 61 (1997), pp. 377-392
[13.]
E. Varon, C. Janoir, M.D. Kitzis, L. Gutmann.
ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.
Antimicrob Agents Chemother, 43 (1999), pp. 302-306
[14.]
S.C. Kampranis, A. Maxwell.
The DNA gyrase-quinolone complex-ATP hydrolysis and the mechanism of DNA cleavage.
J Biol Chem, 273 (1998), pp. 22615-22626
[15.]
C.C. Sanders.
Mechanism responsible for cross-resistance and dichotomous Resistance among the quinolones.
Clin Infect Dis, 32 (2001), pp. S1-S8
[16.]
C.J.R. Willmott, A. Maxwell.
A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex.
Antimicrob Agents Chemother, 37 (1993), pp. 126-127
[17.]
C.C. Sanders.
Microbiology of fluoroquinolones.
Fluoroquinolones in the treatment of infectious diseases, pp. 1-28
[18.]
J.L. Muñoz-Bellido, M.A. Alonzo Manzanares, J.A. Martínez Andrés, M.N. Gutiérrez-Zufiaurre, M. Oriz, M. Segovia Hernández, et al.
Efflux-pump-mediated quinolone resistance in Staphylococcus aureus strains wild-type gyrA, gyrB, grlA and norA.
Antimicrob Agents Chemother, 43 (1999), pp. 354-356
[19.]
A. Mazzariol, Y. Tokue, T.M. Kanegawa, G. Cornaglia, H. Nikaido.
High-level fluoroquinolone-resistant isolates of Escherichia coli overproduce multidrug efflux protein AcrA.
Antimicrob Agents Chemother, 44 (2000), pp. 3441-3443
[20.]
L.J.V. Piddock, D.G. White, K. Gensberg, L. Pumbwe, D.J. Griggs.
Evidence for an efflux pump mediating multiple antibiotic resistance in Salmonella enterica serovar Typhimurium.
Antimicrob Agents Chemother, 44 (2000), pp. 3118-3121
[21.]
L. Martínez-Martínez, A. Pascual, G.A. Jacoby.
Quinolone resistance from a transferable plasmid.
Lancet, 351 (1998), pp. 797-799
[21a.]
J.H. Tran, G.A. Jacoby.
Mechanism of plasmid-mediated quinolone resistance.
Proc Natl Acad Sci USA, 99 (2002), pp. 5638-5642
[22.]
J.S. Wolfson, D.C. Hooper.
Treatment of genitourinary tract infections with fluoroquinolones: Activity in vitro, pharmacokinetics, and clinical efficacy in urinary tract infections and prostatitis.
Antimicrob Agents Chemother, 33 (1989), pp. 1655-1661
[23.]
F. Auquer, F. Cordón, E. Gorina, J.C. Caballero, C. Adalid, J. Batlle, et al.
Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women.
Clin Microbiol Infect, 8 (2002), pp. 50-54
[24.]
K. Gupta, D.F. Sahm, D. Mayfield, W.E. Stamm.
Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: A nationwide analysis.
Clin Infect Dis, 33 (2001), pp. 89-94
[25.]
A.J. Schaeffer.
The expanding role of fluoroquinolones.
Am J Med, 113 (2002), pp. 45-54
[26.]
T. Deguchi, T. Kawamura, M. Yasuda, M. Nakano, H. Fukuda, H. Kato, et al.
In vivo selection of Klebsiella pneumoniae strains with enhanced quinolone resistance during fluoroquinolone treatment of urinary tract infections.
Antimicrob Agents Chemother, 41 (1997), pp. 1609-1611
[27.]
Anonymous. Guidelines for treatment of sexually transmitted diseases.
MMWR, 47 (1998), pp. 1-118
[28.]
M. Rahman, Z. Sultán, S. Monira, A. Alam, K. Nessa, S. Islam, et al.
Antimicrobial susceptibility of Neisseria gonorrhoeae isolated in Bangladesh (1997 to 1999): Rapid shift to fluoroquinolone resistance.
J Clin Microbiol, 40 (2002), pp. 2037-2040
[29.]
R. Sánchez, V. Fernández-Vaca, M.D. Díaz, P. Muñoz, M. Rodríguez, E. Bouza.
Evolution of susceptibilities of Campylobacter species to quinolones and macrolides.
Antimicrob Agents Chemother, 38 (1994), pp. 1879-1882
[30.]
J. Engberg, M. Aarestrup, D.E. Taylor, P. Gerner-Smidt, I. Nachamkin.
Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: Resistance mechanisms and trends in human isolates.
Emerg Infect Dis, 7 (2001), pp. 24-34
[31.]
H.L. DuPont, C.D. Ericsson.
Prevention and treatment of traveler’s diarrhea.
N Engl J Med, 328 (1993), pp. 1821-1827
[32.]
C.D. Ericsson, P.C. Johnson, H.L. Dupont, D.R. Morgan, J.A. Bitsura, F.J. De la Cabada.
Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for travelers’ diarrhea. A placebo-controlled, randomized trial.
Ann Intern Med, 106 (1987), pp. 216-220
[33.]
P. Ginés, M. Navasa.
Antibiotic prophylaxis for spontaneous bacterial peritonitis: How and whom?.
J Hepatol, 29 (1998), pp. 490-494
[34.]
J.P. Rissing.
Antimicrobial therapy for chronic osteomyelitis in adults: Role of the quinolones.
Clin Infect Dis, 25 (1997), pp. 1327-1333
[35.]
L.O. Gentry, G. Rodríguez-Gómez, R.B. Kohler, F.A. Khan, M.W. Rytel.
Parenteral followed by oral ofloxacin for nosocomial pneumonia and community-acquired pneumonia requiring hospitalization.
Am Rev Respir Dis, 145 (1992), pp. 31-35
[36.]
C.A. Peloquin, T.J. Cumbo, D.E. Nix, M.F. Sands, J.J. Schentag.
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication.
Arch Intern Med, 149 (1989), pp. 2269-2273
[37.]
E. Pérez Trallero, J.M. García Arenzana, J.A. Jiménez, A. Peris.
Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin.
Eur J Clin Microbiol Infect Dis, 9 (1990), pp. 905-906
[38.]
J.J. Gordon, C.A. Kauffman.
Superinfection with Streptococcus pneumoniae during therapy with ciprofloxacin.
Am J Med, 89 (1990), pp. 383-384
[39.]
R. Wise, D. Honeybourne.
Pharmacokinetics and pharmacodinamics of fluoroquinolones in the respiratory tract.
Eur Respir J, 14 (1999), pp. 221-229
[40.]
T.M. J.r. File, J. Segreti, L. Dunbar, R. Player, R. Kohler, R.R. Williams, et al.
A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
Antimicrob Agents Chemother, 41 (1997), pp. 1965-1972
[41.]
P. Petitpretz, P. Arvis, M. Marel, J. Moita, J. Urueta.
CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults.
Chest, 119 (2001), pp. 185-195
[42.]
D.M. Musher, M.E. Dowell, V.D. Shortridge, R.K. Flamm, J.H. Jorgensen, P. Le Magueres, et al.
Emergence of macrolide resistance during treatment of pneumococcal pneumonia.
N Engl J Med, 346 (2002), pp. 630-631
[43.]
J. Garau.
Treatment of drug-resistant pneumococcal pneumonia.
Lancet Infect Dis, 2 (2002), pp. 404-415
[44.]
American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia diagnosis, assessment of severity, antimicrobial therapy, and prevention.
Am J Respir Crit Care Med, 163 (2001), pp. 1730-1754
[45.]
J.G. Bartlett, S.F. Dowell, L.A. Mandell, T.M. File, D.M. Musher, M.J. Fine.
Practice guidelines for the management of community-acquired pneumonia in adults.
Clin Infect Dis, 31 (2000), pp. 347-382
[46.]
J. Frías, M. Gomis, J. Prieto, J. Mensa, E. Bouza, J.A. García-Rodríguez, et al.
Tratamiento antibiótico empírico inicial de la neumonía adquirida en la comunidad.
Rev Esp Quimioterap, 11 (1998), pp. 255-261
[47.]
R. Wilson, R. Kubin, I. Ballin, K.M. Deppermann, H.P. Bassaris, P. Leophonte, et al.
Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.
J Antimicrob Chemother, 44 (1999), pp. 501-513
[48.]
F. Álvarez, E. Bouza, J.A. García-Rodríguez, M.A. Mayer, J. Mensa, E. Monsó, et al.
Uso de antimicrobianos en la exacerbación de la enfermedad pulmonar obstructiva crónica.
Rev Esp Quimioterap, 14 (2001), pp. 87-96
[49.]
R. Siegert, P. Gehanno, P. Nikolaidis, D. Bagger-Sjoback, J.M. Ibanez, B. Hampel, et al.
A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group.
Respir Med, 94 (2000), pp. 337-344
[50.]
E. Bouza, M.D. Díaz-López, J.C. Bernaldo de Quiros, M. Rodríguez-Creixems.
Ciprofloxacin in patients with bacteremic infections. The Spanish Group for the Study of Ciprofloxacin.
Am J Med, 87 (1989), pp. 228-231
[51.]
J.E. Peacock, D.A. Herrington, J.C. Wade, H.M. Lazarus, M.D. Reed, J.W. Sinclair, et al.
Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial.
Ann Intern Med, 137 (2002), pp. 77-87
[52.]
J.K. Thomas, A. Forrest, S.M. Bhavnani, J.M. Hyatt, A. Cheng, C.H. Ballow, et al.
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy.
Antimicrob Agents Chemother, 42 (1998), pp. 521-527
[53.]
E. Bouza, F. García-Garrote, E. Cercenado, M. Marín.
Díaz MS for the Spanish Pseudomonas aeruginosa Study Group. Pseudomonas aeruginosa: A survey of resistance in 136 hospitals in Spain.
Antimicrob Agents Chemother, 43 (1999), pp. 981-982
[54.]
J.I. Alós, D. Balas.
Gómez-Garcés JL y Grupo de Estudio de Infección en Atención Primaria. Prevalencia de susceptibilidad a quinolonas y otros antibióticos en microorganismos aislados de bacteriurias extrahospitalarias de Madrid en 1995.
Rev Clin Esp, 197 (1997), pp. 167-171
[55.]
J. Oteo, B. Aracil, J.F. Hoyo, J. Perianes, J.L. Gómez-Garcés, J.I. Alós.
Do the quinolones still constitute a valid empiric therapy for community-acquired urinary tract infections in Spain?.
Clin Microbiol Infect, 5 (1999), pp. 654-656
[56.]
J. Ena, C. Amador, C. Martínez, V. Ortiz de la Tabla.
Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli.
J Urol, 153 (1995), pp. 117-120
[57.]
F. Baquero.
Resistance to quinolones in gram-negative microorganisms: Mechanisms and prevention.
Eur Urol, 17 (1990), pp. 3-12
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
